FDA Approves Rezdiffra for Nonalcoholic Steatohepatitis

FRIDAY, March 15, 2024-- On Thursday, the U.S. Food and Drug Administration announced the approval of Rezdiffra (resmetirom) to treat noncirrhotic nonalcoholic steatohepatitis (NASH) with moderate-to-advanced fibrosis."Previously, patients with...